In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens

作者：Jones Ronald N^*; Bell Jan M; Sader Hello S; Turnidge John D; Stilwell Matthew G

来源：Diagnostic Microbiology and Infectious Disease, 2009, 63(4): 434-439.

DOI：10.1016/j.diagmicrobio.2009.01.025

• Doripenem
• Unusual pathogens
• Carbapenems
• Broad-spectrum

Doripenem, a new 1 beta-methyl parenteral carbapenem, has every broad-spectrum activity against Gram-positive and Gram-negative aerobic bacteria. As noted here, the spectrum and potency extended to many rarely isolated species sampled by the Doripenem Global Surveillance Program. Among the species or species groups with <= 0.14% prevalence (1959 strains tested), doripenem was active against 98.9% of Enterobacteriaceae at <= 0.5 mu g/mL. Similarly more than90% of other rarely isolated Gram-negative species isolates (Aeromonas spp., Delftia acidovorans, Haepmophilus parainfluenzae. Neisseria meningitidis, Ochrobactrum anthropi, Pasteurella multocida. Pseudomonas oryzihabitans, and Pseudomonas stutzeri) were inhibited by <= 2 mu g/mL of doripenem. The low-prevalence Gram-positive pathogens were generally less doripenem susceptible with MIC(90) results at >0.25 mu g/mL for all tested species except Lactococcus garvieae, Listeria monocytogenes and Micrococcus spp. In conclusion, doripenem exhibited a very wide spectrum but variable potencies against uncommonly cultured aerobic bacterial pathogens isolated in 2003 to 2007. These results confirm the potential use of this new carbapenem for broad-spectrum empiric or directed antimicrobial therapy.

• 出版日期2009-4